Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Naved Bhuiyan

Podiatrist Temple Terrace, FL Doctor of Podiatric Medicine

NPI 1982265096 CMS profile 6765898

232 Bullard Pkwy, Temple Terrace, FL 33617

Open in the dashboard

General payments

$10,675

96 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Naved Bhuiyan of Temple Terrace, FL is reported in the CMS Open Payments database as having received $10,675 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,070 14
2024 General $938 9
2023 General $2,790 31
2022 General $3,540 25
2021 General $1,306 16
2020 General $30 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naved Bhuiyan
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Naved Bhuiyan were reported at $2,070. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Naved Bhuiyan Podiatrist median Middle half National median
2019 $0 $196 $72–$601 $163
2020 $30 $118 $38–$335 $114
2021 $1,306 $169 $57–$573 $132
2022 $3,540 $220 $74–$782 $149
2023 $2,790 $208 $71–$635 $160
2024 $938 $237 $87–$681 $164
2025 $2,070 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Integra LifeSciences Corporation $2,944 18 payments
  2. Medical Device Business Services, Inc. $1,448 13 payments
  3. Medline Industries, Inc. $1,130 8 payments
  4. Orthofix Medical, Inc. $964 9 payments
  5. Paragon 28, Inc. $943 2 payments
  6. Arthrex, Inc. $775 6 payments
  7. Stryker Corporation $490 8 payments
  8. AbbVie, Inc. $244 2 payments
  9. Coastal Medical Technologies LLC $240 3 payments
  10. Treace Medical Concepts, Inc. $230 3 payments
  11. Other $1,269 24 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,638 73 payments
  2. Travel and Lodging $4,148 20 payments
  3. Long term medical supply or device loan $1,890 3 payments
Products named General payments · program years 2020–2025
  1. MEDLINE UNITE $4,521 32 payments
  2. AMNIOEXCEL PLUS $1,502 1 payment
  3. Integra Recon-Skin And Wound $975 13 payments
  4. TrueLok $964 9 payments
  5. Product Portfolio $943 2 payments
  6. Integra Recon-Skin And Wound $842 12 payments
  7. Integra Recon-Skin And Wound $842 12 payments
  8. INTEGRA DERMAL REGENERATION TEMPLATE $842 12 payments
  9. PRIMATRIX $842 12 payments
  10. ACell $255 1 payment
  11. Other $3,027 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

581

Median for Podiatry: 160

Drug cost

$12,801

Median for Podiatry: $2,368

Branded share of claims

21%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 133 $4,155
Ciclopirox Generic 87 $2,763
Ammonium Lactate Generic 81 $2,089
Ciclopirox Ciclopirox Olamine Brand 87 $1,383
Ketoconazole Generic 12 $796
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 35 $424
Meloxicam Generic 54 $317
Clotrimazole Generic 15 $257
Mupirocin Generic 31 $220
Methylprednisolone Generic 21 $179

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$171,351

Medicare's payments for the services billed

Medicare patients

289

Average age 75

Services billed

836

156 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Diabetes 58%
Ischemic heart disease 54%
Chronic kidney disease 52%
Depression 47%
Heart failure 38%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record